Pharma
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
ReadCommented by André Will-Laudien on May 27th, 2025 | 07:15 CEST
Up to 1500% with high tech and artificial intelligence – Incredible price movements at Evotec, NetraMark Holdings, and D-Wave
Artificial intelligence can now be found in all sectors of the economy. Search processes, validations, and historical comparisons now take place in a matter of seconds, and a dramatic leap in productivity is on the horizon. The capital markets have set themselves the task of evaluating these future processes. This is no easy task, as most topics cannot be viewed in isolation. Last week, renewed tariff threats led to a short-term price correction. These losses had to be offset yesterday, with political denials from the US sending share prices skyrocketing again. Under intense pressure, investors now have to decide whether investments promise short- or medium-term success. We use three examples to show how challenging this has become. Where are the opportunities and risks?
ReadCommented by Stefan Feulner on May 27th, 2025 | 07:05 CEST
Bayer, Desert Gold, Snowflake – Breakout imminent
US President Donald Trump's tariff hammer against the European Union caused stock markets to falter at the close of the trading week, but the postponement of the measures by four weeks eased tensions over the weekend. As a result, Germany's leading index, the DAX, got off to a flying start to the week, regaining the 24,000-point mark. However, uncertainties remain, meaning the safe haven gold could once again rise to new highs.
ReadCommented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST
Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva
In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?
ReadCommented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
ReadCommented by Armin Schulz on May 14th, 2025 | 07:00 CEST
Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits
The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.
ReadCommented by Nico Popp on May 13th, 2025 | 07:10 CEST
The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma
Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.
ReadCommented by Armin Schulz on May 8th, 2025 | 07:05 CEST
Cancer revolution: How Bayer, Vidac Pharma, and Pfizer are shaking up the billion-dollar market
Oncology has become the scene of an unprecedented competition. Where billion-dollar markets meet life-saving innovations, a global playing field for pioneers is emerging. Forecasts show that therapy costs and market volume are growing exponentially. This poses a challenge for healthcare systems and represents a gold mine for visionaries. New technologies such as personalized cancer vaccines and targeted drugs are pushing the boundaries of what is possible. Three players are strategically positioning themselves in this dynamic environment: Bayer, Vidac Pharma, and Pfizer. Their next moves could shape not only patients' lives, but entire industries.
ReadCommented by Armin Schulz on May 7th, 2025 | 07:10 CEST
Evotec's AI gold mine, Defence Therapeutics' billion-dollar markets, Novo Nordisk's diet revolution: How investors are profiting
The healthcare industry is undergoing radical change. Algorithms are accelerating drug discovery by years, billions are being poured into personalized therapies, and biotech stocks are celebrating on the stock markets. But this time, it is not just short-lived hype – the next era of medicine will be shaped by companies merging technology and biology. While AI-based platforms identify drug candidates in record time, pioneers are pushing ahead with groundbreaking approaches in oncology, immunology, and metabolic diseases. Three names stand out: Evotec, Defence Therapeutics, and Novo Nordisk.
ReadCommented by Armin Schulz on May 6th, 2025 | 07:05 CEST
Soil boosters wanted! The secret weapons of Bayer, Argo Living Soils, and K+S
Agriculture is at a crossroads between tradition and revolution. While optimistic forecasts like the Iowa Crop Progress Report 2025 predict record-breaking harvests, a paradoxical conflict is emerging. Blooming fields conceal depleting soils and climate stress. But this is precisely where the tension for innovation unfolds - where high-tech meets sustainability. Three players are helping to shape this future: Bayer as a pioneer of digital agricultural solutions; Argo Living Soils with revolutionary soil savers; and K+S, which is rethinking mineral fertilizers. Together, they are not only securing harvests but also healing ecosystems.
Read